Ribero Dario, Abdalla Eddie K, Thomas Melanie B, Vauthey Jean-Nicolas
Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
Expert Rev Anticancer Ther. 2006 Apr;6(4):567-79. doi: 10.1586/14737140.6.4.567.
Hepatocellular carcinoma is a leading cause of cancer death worldwide. Liver resection and liver transplantation remain the only options for cure. Since the indications for orthotopic liver transplantation are limited, partial liver resection is the more common treatment. Recently, indications for liver resection have been expanded and there have been advances in the associated surgical techniques. This review describes the state-of-the-art of liver resection for hepatocellular carcinoma. Topics covered include: new indications, such as treatment of large tumors, bilobar tumors and those associated with vascular invasion; preoperative assessment of liver function; and surgical strategies. An overview of the most common staging systems, which are useful in predicting prognosis after liver resection for hepatocellular carcinoma, is given.
肝细胞癌是全球癌症死亡的主要原因。肝切除和肝移植仍然是唯一的治愈选择。由于原位肝移植的适应症有限,部分肝切除是更常见的治疗方法。近年来,肝切除的适应症有所扩大,相关手术技术也取得了进展。本综述描述了肝细胞癌肝切除的最新进展。涵盖的主题包括:新的适应症,如大肿瘤、双叶肿瘤以及与血管侵犯相关的肿瘤的治疗;肝功能的术前评估;以及手术策略。还概述了最常用的分期系统,这些系统有助于预测肝细胞癌肝切除术后的预后。